IFNα versus IFNα Plus Octreotide LAR in Treatment of NETs Abstract #1091

Introduction: It is still unknown whether the combination of IFNα with octreotide LAR has benefit compared with IFNα alone
Aim(s): Тo compare efficacy and toxicyty of IFNα and IFNα plus Octreotide LAR in first line of therapy of patients with NETs
Materials and methods: 50 pts with morphologically verified well differentiated advanced NETs(G1-2), 16 (32%) men and 34 (68%) women, mean age 55 (19-80). IFNα(n=19): lung–11(58%); GEP–8(42%). Grade: G1–8(42%); G2–11(58%). IFNα+Octreotide LAR(n=31): lung–6(19%); GEP–25(81%).Grade:G1–11(35%); G2–20(65%)
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Galina Emelianova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#659 Everolimus in Patients with Previously Treated Metastatic Neuroendocrine Tumors (NETs)
Introduction: Everolimus is the standard of care in well-differentiated NETs. Previous randomized trials included patients treated with a maximum of two lines of prior chemotherapy. We evaluated everolimus in heavily pretreated patients with NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Alexander Kuzminov
#910 Experience of Temozolomide Mono- and Combination Therapy in Advanced Neuroendocrine Tumors (NETs) in Russia
Introduction: Temozolomide (T) demonstrated promising activity in NETs in numerous phase 2 studies worldwide. But there is not enough data about its efficacy in the Russian population.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Alexander Kuzminov
#1275 Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova
#1294 The Efficacy and Safety of Sunitinib in Heavily Pretreated Patients with NETs. National Cancer Research Center Experience.
Introduction: There was done monocentral trial. 19 pts with progressive well differentiated NETs (G1,G2) were treated with sunitinib
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Anastacia Odintsova
#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Svetlana Polozkova